15. November 2023 – Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens, today announced the completion of its oversubscribed Series C equity financing raising €67.5 million ($72 million) from a syndicate of renowned international healthcare investors.

The Series C round was co-led by Andera Partners, Bpifrance (through its InnoBio 2 fund) and M Ventures, with participation from Revelation Partners, Indaco Venture Partners, Panakès Partners, XGen Ventures, and other undisclosed investors together with continued support from existing investors 5AM Ventures, EQT Life Sciences and Versant Ventures. Concurrent with the financing, representatives from Andera Partners, Bpifrance and M Ventures have joined the Nouscom Board of Directors.

The proceeds will be used to continue advancing and expanding Nouscom’s wholly owned clinical pipeline to achieve multiple clinical value catalysts.

Walder Wyss advised the investors in the transaction. The Walder Wyss team was led by Alexander Gutmans (Partner, Corporate/M&A and Venture Capital) and Karina Tschon (Senior Associate, Corporate/M&A and Venture Capital), and further included Benjamin Suter (Counsel, Commercial Contracts), Michelle Bruni (Managing Associate, Tax), Lucas Maurer (Associate, Corporate/M&A and Venture Capital), Simon Olstein (Associate, Corporate/M&A and Venture Capital), Christoph Burckhardt (Associate, Corporate/M&A and Venture Capital) and Dario Glauser (Associate, Employment).